Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | — |
By accident the patient took Vivotif two days in a row; Case reference number US-BN-2025-001952 is a spontaneous case initially received from pharmacist via Bavarian Nordic (reference number: CASE-001169) on 12-Dec-2025 and concerns a 27-year-old female patient. The patient's medical history and concomitant medication details were not provided. On an unknown date, the patient took the first dose of Vivotif (batch number: unknown) at an unknown dose and route of administration for an unknown indication. On an unknown date, day after the first dose, the patient took the second dose of Vivotif (batch number: unknown) at an unknown dose and route of administration for an unknown indication (explicitly coded as 'inappropriate schedule of product administration'). At the time of the initial report, the patient did not experience any adverse events due to the Vivotif vaccine. No further information was provided.; Reporter's Comments: A 27-year-old female patient took Vivotif for an unknown indication two days in a row, which is considered as inappropriate schedule of product administration. The patient did not experience any adverse events due to the Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 27-year-old female patient took Vivotif for an unknown indication two days in a row, which is considered as inappropriate schedule of product administration. The patient did not experience any adverse events due to the Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.